Home › Acute Myeloid Leukemia › Texas
Acute Myeloid Leukemia clinical trials in Texas
97 studies for Acute Myeloid Leukemia are looking for participants at sites in Texas.
Cities in Texas
- Houston88 studies
- Dallas20 studies
- Austin5 studies
- San Antonio5 studies
- Fort Worth4 studies
- Corpus Christi3 studies
CD70.CAR for AML and Other CD70+ Leukemias
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
RecruitingPhase 1
Up to age 75 · All sexes · Updated Nov 13, 2026 · NCT06345027Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06317649Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
- UT MD Anderson, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07549464Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- M D Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04774393Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Nov 12, 2026 · NCT02115295Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Texas Oncology-Austin Midtown, Austin
- Texas Oncology-Presbyterian Cancer Center, Dallas
- University of Texas, Houston
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07007312Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Nov 10, 2026 · NCT03589729Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Baylor University Medical Center, Dallas
- Houston Methodist Cancer Center, Houston
- MD Anderson Cancer Center, Houston
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06852222Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 15 to 80 · All sexes · Updated Nov 2, 2026 · NCT02727803MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT05564390Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- M D Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT03214562Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- Baylor Charles A. Sammons Cancer Center, Dallas
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 30, 2026 · NCT05429632A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
- MD Anderson Cancer Center, Houston
RecruitingObservational study
All ages · All sexes · Updated Oct 30, 2026 · NCT06906380Study of REM-422 in Patients With AML or Higher Risk MDS
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06297941Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 29, 2026 · NCT06131801CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- MD Anderson, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT05143996Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Oct 28, 2026 · NCT05554393Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Houston
RecruitingPhase 1/2
Ages 16 and older · All sexes · Updated Oct 23, 2026 · NCT07155226A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT06969430A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
RecruitingPhase 1
Up to age 21 · All sexes · Updated Oct 23, 2026 · NCT07012044Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- UT Southwestern/Simmons Cancer Center, Dallas
- Cook Children's Medical Center, Fort Worth
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Oct 22, 2026 · NCT06177067A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- The University of Texas MD Anderson Cancer Center /ID# 279402, Houston
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07581002CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 to 85 · All sexes · Updated Oct 21, 2026 · NCT06834282Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Clinical Trial Site, Houston
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Oct 21, 2026 · NCT07211958Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06533761A Study of Revumenib and Mezigdomide in People With Leukemia
- MD Anderson Cancer Center (Data Collection Only), Houston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 20, 2026 · NCT07356154Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT06846606Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
- M.D. Anderson Cancer Center, Department of Leukemia, Houston
RecruitingPhase 1Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT05986240PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
- M D Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT02390635Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
- M D Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT05010772A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06616636Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
- Houston Methodist Neal Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07060001A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT04256317Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- M D Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT04140487Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
- The University of Texas M. D. Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT06811233A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Children's Medical Center Dallas /ID# 275930, Dallas
RecruitingPhase 1
6 Months – 17 Years · All sexes · Updated Oct 5, 2026 · NCT07306832Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 50 and older · All sexes · Updated Oct 5, 2026 · NCT03586609A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT03629171From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.